Objective:To investigate the antimicrobial properties of copper-loaded coatings on the surface of ureteral stents and their biocompatibility in order to determine the most suitable level of copper loading.Methods:Copper-loaded PDA coatings with different copper contents were constructed on the surface of polyurethane (PU) stents using polydopamine (PDA) and dimethylaminomethylborane (DMAB). The antibacterial property of the coating against Escherichia coli and Staphylococcus aureus was investigated by the plate counting method. The bacterial adhesion on the coating surface was studied by scanning electron microscopy. Using the live/dead evaluation, microbes were stained and observed by a fluorescence microscope. The biocompatibility of the copper-loaded coatings was detected by a cell proliferation assay incubated with L929 cells.Results:The antibacterial rates of the copper-loaded samples exceeded 90% after incubation with E. coli and S. aureus for 24 h, respectively, and the antibacterial performance increased with the increase of copper content in the coating. The amount of bacteria adhered to the surface of the copper-loaded samples was significantly lower, and most of them were dead bacteria. When the copper content in the coating preparation solution used was 0.25~1 g/L, the cell proliferation rate on the surface of the copper-loaded coating was higher than 80% and the material was not cytotoxic.Conclusions:A copper-loaded PDA coating with excellent antibacterial properties and good biocompatibility can be prepared with a copper content of 1 g/L in the coating preparation solution, forming a potential solution for the preparation of ureteral stent coatings.

Objective:To observe whether α1 adrenergic receptor (α1AR) blocker can reduce and antagonize portal hypertension caused by α1AR activation in rats, and to provide a new approach for the clinical treatment of portal hypertension.Methods:Phenylephrine was chosen as α1AR agonist, and alfuzosin was used as α1AR blocker. The route of administration was portal vein injection, and the pressure was measured by trans-portal vein puncture. According to random number table, 32 male Sprague-Dawley rats were divided into 4 groups: control group, portal hypertension model group, alfuzosin treatment group and alfuzosin prevention group. The portal venous pressure (PVP) was measured in all rats before administration. The rats in the control group were injected with 0.9% sodium chloride solution (1 L/g), and the rats in portal hypertension model group were injected with phenylephrine(1.5 μg/g), and the PVP of the above two groups was measured again at 5 and 10 min after injection. The rats in alfuzosin treatment group were injected with phenylephrine(1.5 μg/g), PVP was measured again at 5 min after administration, and then the rats were given alfuzosin(0.9 μg/g), PVP was measured again at 5 min after administration. The rats in alfuzosin prevention group were injected with alfuzosin(0.9 μg/g), PVP was measured at 1 min after administration, and then the rats were given phenylephrine(1.5 μg/g), PVP was measured again at 1, 5 and 10 min after phenylephrine injection respectively. One way analysis of variance and Dunnett- t test were used for statistical analysis. Results:The portal vein puncture was successfully performed in 4, 6, 8 and 5 rats in the control group, portal hypertension model group, alfuzosin treatment group and alfuzosin prevention group, respectively. The PVP of rats in portal hypertension model group at 5 and 10 min after phenylephrine injection was (18.045±7.636) and (15.515±5.440) mmHg (1 mmHg = 0.133 kPa), respectively, which were both higher than that before administration ((8.452±2.830) mmHg), and the differences were statistically significant ( t=2.89 and 2.82, both P<0.05). At 5 min after alfuzosin injection, the PVP of rats in the alfuzosin treatment group was (10.088±3.743) mmHg, which was lower than that of rats at 5 min after phenylephrine injection ((16.146±4.324) mmHg) and that of portal hypertension model group at 10 min after phenylephrine injection, and the differences were statistically significant ( t=3.00 and 2.22, both P<0.05). There were no significant differences in PVP in the alfuzosin prevention group before administration, at 1 min after injection of alfuzosin, and at 1, 5 and 10 min after injection of phenylephrine (all P > 0.05). Conclusions:α1AR is an important factor involved in the regulation of PVP, and its blockers can reduce and antagonize the portal hypertension caused by α1AR activation, which is of great significance in the prevention and treatment of portal hypertension progression in liver cirrhosis.

Objective:To detect serum levels of vitamin A (Vit A), vitamin D(Vit D)25-hydroxy vitamin D[25-(OH)D] and vitamin E(Vit E) in children aged 0-6 years in Tibetan Plateau of Garzi Prefecture, thus providing references for physical examinations and prevention of 4 key diseases (rickets, malnutrition anemia, pneumonia and diarrhea) in children in plateau areas by relevant government departments.Methods:A total of 2 122 children who participated in physical examination in 12 townships of Xiangcheng County and 14 townships of Daocheng County, Garzi Tibetan Autonomous Prefecture, Sichuan Province from April 2017 to April 2019 with 0-6 years old were recruited for surveying physical measurements and collection of venous blood.Serum Vit A and Vit E levels were detected by high performance liquid chromatography.Serum levels of 25-(OH)D were detected by high performance liquid chromatography tandem mass spectrometry.The relationship between Vit A, Vit E and 25-(OH)D levels with the gender, age, seasonal change and altitude was analyzed.Results:The serum Vit A level, subclinical Vit A deficiency rate and marginal vitamin A deficiency rate were(1.05±0.27) μmol/L, 8.15%(173/2 122 cases) and 45.99%(976/2 122 cases), respectively in 2 122 children with 0-6 years old.There were significant differences in the serum Vit A level, the subclinical Vit A deficiency rate and the marginal vitamin A deficiency rate in children with different ages, seasons and altitudes (all P<0.05). The serum level of 25-(OH)D and 25-(OH)D deficiency rate insufficient rate were (24.65±6.45) ng/L, 6.03%(128/2 122 cases) and 16.59%(352/2 122 cases), respectively.There were significant differences in the serum level of 25-(OH)D, 25-(OH)D deficiency rate and 25-(OH)D insufficient rate in children with different ages and seasons (all P<0.05). The mean serum Vit E level, Vit E deficiency rate and Vit E insufficient rate were (7.81±1.74) mg/L, 2.78%(59/2 122 cases) and 29.59%(628/2 122 cases), respectively.There were significant differences in serum Vit E level, Vit E deficiency rate and Vit E insufficient rate in children with different ages and seasons (all P<0.05). The mean serum levels of Vit A and Vit D remained the lowest before the age of 1 year, and their deficiencies at this age were the most significant.The mean serum level of Vit E remained the lowest in >1-2 years old, and its deficiency and insufficient at this age were the most significant.Vit A, D and E levels were significantly affected by seasonal changes, which were significantly higher in the summer than in the spring, autumn and winter.In addition, Vit A and 25-(OH)D were significantly affected by the altitude, which were the lowest above 4 km altitude. Conclusions:The overall serum levels of Vit A, 25-(OH) D and E in children with 0-6 years old in Tibetan Plateau areas of Ganzi Prefecture are lower than those in plain areas.Vit A, 25-(OH) D and Vit E levels significantly differed in the age, season and altitude, which are related to the lack of local resources, insufficient maternal nutrition during pregnancy and insufficient intake after birth, as well as temperature and light caused by changes in local seasons and altitude.Therefore, it is necessary to make reasonable supplements during pregnancy to prevent vitamin deficiency.

Objective:To describe the current status of registration and design characteristics of clinical trials of new drugs for curing hepatitis B through domestic and foreign websites, so as to provide references for the follow-up clinical trials of new hepatitis B drugs.Methods:A search was conducted on the US Clinical Trials Database and the Chinese Clinical Trial Registry Center. The search date was from the establishment of the database to May 26, 2020, and the registration trials of new drugs for curing hepatitis B at home and abroad were included. Two researchers independently searched and screened the literature and extracted the data.Results:A total of 106 registered clinical trials of new drugs for curing hepatitis B were included (94 English registration websites and 12 Chinese registration websites), and the number of registrations had increased year by year. Among them, the proportion of therapeutic vaccines and core protein inhibitors were the highest, accounting for 27.4% ( n = 29) and 22.6% ( n = 24), respectively. The vast majority of clinical trials ( n = 96, 90.6%) were in the early stages (Phase I and II). The subjects in phase I clinical trial were mainly healthy people and treated CHB patients, while the subjects in phase II clinical trial were mainly CHB patients who had achieved viral suppression after initial or post-treatment. The main evaluation indicators of Phase I clinical trials were the safety and tolerability of new drugs. The main evaluation indicators in about half of Phase II clinical trials were HBsAg negative conversion/quantitative decline. Overall, the number of clinical trials with the new design was small, accounting for 3.8% (4 / 106). There were relatively few trials of new drugs for curing hepatitis B on domestic registration websites, and the information provided was incomplete. Conclusion:The number of clinical trials of new hepatitis B drugs at home and abroad is increasing year by year, but most of them are in phase I and II, with few adopting new designs. In addition, the information integrity of the domestic website registration center needs to be improved.

Objective To evaluate the scientific research efficiency of tertiary hospitals and analyze the influencing factors, providing reference for the decision-making of scientific research managers in China. Methods Evaluation indicators were collected from 100 tertiary hospitals in China, and their research efficiency was evaluated using Bootstrap data envelopment analysis (DEA) method. The influencing factors were analyzed using ordinary least square ( OLS) regression model. Results The averaged scientific research efficiency of these hospitals using Bootstrap DEA method was 0. 5224, lower than that using conventional DEA method (0. 0676), yet with a great variation (from 0. 1103 to 0. 8790) among them. Linear regression analysis showed that factors such as R&D input and output, and hospital types has statistical significance on the saentific research efficiency (P < 0. 05). Conclusions These hospitals are inefficient in scientific research with sizable room for improvement. Conventional DEA method should be used with caution, as deviations should be corrected with Bootstrap DEA method. The research development level and hospital types of their province can influence the research efficiency the hospitals significantly.

Objective To investigate the effect of Tongxinluo on carotid artery stenosis,and the levels of high sensitive C reactive protein(hs-CRP) and D-Dimer in patients with cerebral infarction.Methods 168 patients with cerebral infarction treated in this hospital from June 2014 to June 2015 were randomly divided into experimental group and control group,with 84 cases in each group.The patients in both group received routine treatment.In addition to that,patients in the experimental group also used Tongxinluo capsule for 6 months as a course of treatment.After a course of treatment,Doppler ultrasound diagnosis instrument was used to detect carotid arterial intima-media thickness,plaque area and carotid artery stenosis rate.Hs-CRP and D-Dimer levels were also detected.Results After treatment,the carotid arterial intima-media thickness,plaque area and carotid vascular stenosis rate in two group were significantly decreased(P<0.05),but the three indicators in experimental group were decreased more significantly(P<0.05).After a course of treatment,the levels of D-Dimer and hs-CRP in peripheral blood of the two groups were significantly decreased(P<0.05),but the content of D-Dimer and hs-CRP was much lower in the experimental group(P<0.05).Conclusion Tongxinluo treatment could effectively reduce the level of hs-CRP and D-Dimer in patients with cerebral infarction,and alleviate the carotid artery stenosis,which might be worthy of clinical application.

Objective To systematically assess the application status of evaluation indicators of research efficiency in research institutions in China.Methods Literatures published before August 2016 were searched and retrieved from CNKI and Wanfang Database.Results 112 indicators used in 72 literatures were merged and analyzed.According to the usage frequency not less than 10％ and the top usage frequency in each indicator group,the main input indicators involved the number of total researchers and the total research funding.The output indicators mainly focused on the number of monographs,the number of academic papers,the number of patents granted,the number of research projects,the number of awards and the amount of money charged for technology transfer.Conelusions The indicators obtained from the previous research could provide a reference for the research efficiency evaluation of medical institutions in China.

After the factors that influence the selection of words were analyzed according to the problems in selec-tion of words for co-word analysis, a hypothesis for how to select the word sets with its verification analysis was pro-posed, the method for selecting words was thus decided according to the word frequency-covered literature area and the number of high frequency words. However, its practical use in large data sets needs to be further improved.

Objective To investigate the relationship between changes of aldosterone level and renal function during perioperative period of renal transplantation and preliminarily discuss the role of aldosterone in chronic allograft nephropathy.Methods One hundred patients undergoing allogeneic renal transplantation in the Department of Urology of the General Hospital of Shenyang Military from January 1 ,201 0 to December 31 ,201 3 were assigned into the experimental group.According to the Scr levels measured at 30 d after renal transplantation,1 00 patients were divided into groups A (Scr≥1 33 μmol/L,n =1 3)and B (Scr <1 33 μmol/L,n =87).Ten healthy individuals aged 25-35 years were recruited into the control group.In the experimental group,blood sample was collected in the morning upon the day of renal transplantation (0 d),1 ,7,1 5 and 30 d after renal transplantation.In the control group,blood sample was obtained at the same time points for measurement of aldosterone and Scr levels.Results On the day of renal transplantation,the Scr level in the experimental group was (598 ±37)μmol/L,significantly higher compared with (75 ±5)μmol/L in the control group (P <0.05).The aldosterone level in the experimental group was (0.26 ±0.06)ng/dl,considerably higher than (0.1 3 ±0.03) ng/dl in the control group (P <0.05).Compared with 0 d,the Scr levels of group A significantly decreased at postoperative 30 d (P <0.05),whereas no statistical significance was noted in aldosterone levels between two time points (P >0.05).In group B,both Scr and aldosterone levels were significantly decreased at postoperative 30 d (both in P <0.05).Correlation analysis revealed that the serum level of aldosterone was positively correlated with Scr level changes (r =0.85,P <0.05).Conclusions After renal transplantation,change of Scr level is positively correlated with aldosterone level alterations, probably suggesting that aldosterone plays a partial role in mediating injury of transplant kidney during renal transplantation.

The limitations of patent ranking were analyzed, followed by a description of the patent asset index, a novel approach to benchmark patent porifolios, which assesses patents according to their portfolios, market and technologies, and is thus a more accurate tool for assessing the value of intellectual property rights.